BioWorld Asia

June 15, 2011

4SC Stock Plummets on Vidofludimus Miss in RA

Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International) Read More

Ipsen Restructures to Focus on Peptides and Toxins

Heart Stem Cells Can Make New Muscle, Study Shows

Quintiles Takes Equity Stake in Kareus Therapeutics

New Leadership Takes Over at Embattled Agency

UK Government Funds Tumor Profiling Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...